Department of Assisted Reproduction, Shanghai Ninth People's Hospital Affiliated to JiaoTong University School of Medicine, Shanghai, People's Republic of China.
Drug Des Devel Ther. 2020 Dec 1;14:5289-5297. doi: 10.2147/DDDT.S281451. eCollection 2020.
To investigate the effects of sildenafil citrate (SC) on live birth rates (LBR) during women undergoing their first frozen embryo transfers (FET) with hormone replacement therapy (HRT).
This retrospective cohort study included a total of 10,069 infertile women with adequate endometrial thickness (≥7 mm when progesterone was initiated) in their first FET cycle with hormone replacement therapy. Women received either vaginal SC or no adjuvant during their first transfer cycle depending on patient or physician preference. In the sildenafil group, 1098 women underwent HRT FET with adjuvant vaginal use of SC, and 8971 women were included as controls. The primary outcome measure was LBR, defined as the likelihood of live birth per transfer cycle. Endometrial thickness (EMT), implantation, chemical pregnancy, clinical pregnancy, miscarriage, ongoing pregnancy, birth weight and preterm delivery (PTB) were also recorded.
Baseline characteristics were comparable between the two groups. In the crude analysis, the unadjusted LBR was significantly higher in the vaginal SC group (scHRT-FET) than in the control group (HRT-FET) (40.3% vs 36.1%). After adjustment for 12 pregnancy-related confounding factors, logistic regression analysis showed that LBR remained significantly higher in the scHRT-FET group than in the HRT-FET group (adjusted odds ratio [aOR] 1.31, 95% confidence interval [CI] 1.14-1.49). Furthermore, after adjustment, the ongoing pregnancy rate was significantly higher (aOR 1.29, 95% CI 1.13-1.47), and the miscarriage rate was significantly lower (aOR 0.58, 95% CI 0.43-0.77), in the scHRT-FET group compared to the HRT-FET group. Adjuvant vaginal use of SC did not increase the endometrial thickness and had no significant effect on birth weight or PTB.
Adjuvant vaginal use of SC in HRT FET was associated with higher LBR and improved pregnancy outcomes in an infertile population with adequate endometrial thickness. The beneficial effect of SC may be due not to an increase in EMT but instead to improve endometrial blood flow and receptivity, which might merit clinicians' attention for improving general IVF practices.
研究枸橼酸西地那非(SC)对接受激素替代疗法(HRT)的首次冻融胚胎移植(FET)女性活产率(LBR)的影响。
这是一项回顾性队列研究,共纳入了 10069 名首次 FET 周期中接受 HRT 的不孕女性,这些女性的子宫内膜厚度充足(当开始使用孕激素时≥7mm)。根据患者或医生的偏好,女性在首次移植周期中接受阴道 SC 或不接受辅助治疗。在 SC 组中,1098 名女性接受 HRT-FET 并辅助阴道使用 SC,8971 名女性作为对照组。主要结局指标是活产率,定义为每个移植周期的活产可能性。还记录了子宫内膜厚度(EMT)、着床、化学妊娠、临床妊娠、流产、持续妊娠、出生体重和早产(PTB)。
两组的基线特征无差异。在未校正分析中,阴道 SC 组(scHRT-FET)的未校正 LBR 明显高于对照组(HRT-FET)(40.3% vs. 36.1%)。在调整了 12 个与妊娠相关的混杂因素后,逻辑回归分析显示,scHRT-FET 组的 LBR 仍然明显高于 HRT-FET 组(调整后的优势比[aOR]1.31,95%置信区间[CI]1.14-1.49)。此外,调整后,scHRT-FET 组的持续妊娠率显著升高(aOR 1.29,95% CI 1.13-1.47),流产率显著降低(aOR 0.58,95% CI 0.43-0.77)。阴道 SC 的辅助使用并未增加子宫内膜厚度,对出生体重或 PTB 没有显著影响。
在子宫内膜厚度充足的不孕人群中,HRT-FET 中辅助阴道使用 SC 可提高 LBR 和改善妊娠结局。SC 的有益效果可能不是由于 EMT 的增加,而是由于改善了子宫内膜血流和容受性,这可能值得临床医生关注,以改善常规 IVF 实践。